Protagonist Therapeutics, IncPTGXEarnings & Financial Report
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.
PTGX Q4 FY2024 Key Financial Metrics
Revenue
$170.6M
Gross Profit
N/A
Operating Profit
$126.8M
Net Profit
$131.7M
Gross Margin
N/A
Operating Margin
74.3%
Net Margin
77.2%
YoY Growth
184.4%
EPS
$2.01
Protagonist Therapeutics, Inc Q4 FY2024 Financial Summary
Protagonist Therapeutics, Inc reported revenue of $170.6M (up 184.4% YoY) for Q4 FY2024, with a net profit of $131.7M (up 381.7% YoY) (77.2% margin).
Key Financial Metrics
| Total Revenue | $170.6M |
|---|---|
| Net Profit | $131.7M |
| Gross Margin | N/A |
| Operating Margin | 74.3% |
| Report Period | Q4 FY2024 |
Protagonist Therapeutics, Inc Quarterly Revenue & Net Profit History
Protagonist Therapeutics, Inc results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2024 | $170.6M | +184.4% | $131.7M | 77.2% |
| Q1 FY2024 | $255.0M | — | $207.3M | 81.3% |
| Q3 FY2023 | $0 | — | $-34.1M | N/A |
| Q2 FY2023 | $0 | — | $-38.5M | N/A |
| Q1 FY2023 | $0 | — | $-33.7M | N/A |
| Q4 FY2022 | $0 | — | N/A | N/A |
| Q3 FY2022 | $0 | — | $-31.2M | N/A |
Income Statement
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q1 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $255.0M | $170.6M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | 184.4% |
Balance Sheet
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q1 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|
| Assets | $282.2M | $247.9M | $239.9M | $320.5M | $330.0M | $629.3M | $744.7M |
| Liabilities | $38.6M | $32.3M | $23.7M | $26.4M | $27.9M | $68.8M | $69.4M |
| Equity | $243.6M | $215.6M | $216.2M | $294.1M | $302.1M | $560.4M | $675.3M |
Cash Flow
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q1 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-25.2M | $-108.1M | $-34.3M | $-26.2M | $-26.6M | $-27.4M | $184.2M |